We all know the vital precautions to keep babies safe from respiratory syncytial virus (RSV). While the virus is the leading ...

The Lice Treatment Global Market Report 2024 from ResearchAndMarkets.com reveals that there has been a 'global rise in the ...

Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

Current methods to deliver bacteria to the bladder are invasive and require repeated catheter insertion. Even when bacteria ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Committee for Medicinal Products for Human ...

RSV hospitalizations in US adults reached high levels pre-vaccine, especially impacting those 75 and older, underscoring the ...

An international, Phase III clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare ...

The AD risk factors/hits include high exposure to traffic-related air pollution (TRAP) and infections, as well as factors ...

One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.